{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:56:37Z","timestamp":1762980997736,"version":"3.37.3"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11886-020-01409-8","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T11:02:41Z","timestamp":1602327761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Management of Patients with Acute Coronary Syndrome and Cancer"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3157-2584","authenticated-orcid":false,"given":"Tyler B.","family":"Moran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Plana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"key":"1409_CR1","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","volume":"61","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2013;61:e78\u2013e140.","journal-title":"J Am Coll Cardiol"},{"key":"1409_CR2","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2014;64:e139\u2013228.","journal-title":"J Am Coll Cardiol"},{"key":"1409_CR3","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jacc.2015.10.005","volume":"67","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2015 ACC\/AHA\/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction. J Am Coll Cardiol. 2016;67:1235\u201350.","journal-title":"J Am Coll Cardiol"},{"key":"1409_CR4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/clc.22007","volume":"35","author":"SW Yusuf","year":"2012","unstructured":"Yusuf SW, Daraban N, Abbasi N, Lei X, Durand J-B, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35:443\u201350.","journal-title":"Clin Cardiol"},{"key":"1409_CR5","first-page":"1","volume":"68","author":"K Kochanek","year":"2017","unstructured":"Kochanek K, Murphy S, Xu J, Arias E. Deaths: final data for. Natl Vital Stat Rep. 2017;68:1\u201377.","journal-title":"Natl Vital Stat Rep"},{"key":"1409_CR6","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1161\/CIRCULATIONAHA.117.030798","volume":"136","author":"E Puymirat","year":"2017","unstructured":"Puymirat E, Simon T, Cayla G, Cottin Y, Elbaz M, Coste P, et al. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI program (French registry of acute ST-elevation or non-ST-elevation myocardial infarction) 1995 to 2015. Circulation. 2017;136:1908\u201319.","journal-title":"Circulation"},{"key":"1409_CR7","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/eurheartj\/ehm031","volume":"28","author":"G Montalescot","year":"2006","unstructured":"Montalescot G, Dallongeville J, Van Belle E, Rouanet S, Baulac C, Degrandsart A, et al. STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC\/ACC definition (the OPERA registry). Eur Heart J. 2006;28:1409\u201317.","journal-title":"Eur Heart J"},{"key":"1409_CR8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1161\/CIRCOUTCOMES.115.002312","volume":"9","author":"AN Vora","year":"2016","unstructured":"Vora AN, Wang TY, Hellkamp AS, Thomas L, Henry TD, Goyal A, et al. Differences in short- and long-term outcomes among older patients with ST-elevation versus non\u2013ST-elevation myocardial infarction with angiographically proven coronary artery disease. Circ Cardiovasc Qual Outcomes. 2016;9:513\u201322.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1409_CR9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/2048872617706501","volume":"7","author":"M Iannaccone","year":"2018","unstructured":"\u2022 Iannaccone M, D\u2019Ascenzo F, Vadal\u00e0 P, et al. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care. 2018;7:631\u20138 Multicenter study evaluating outcomes of cancer patients with MI, and benefit of medical therapy.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"1409_CR10","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","volume":"420","author":"P Libby","year":"2002","unstructured":"Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868\u201374.","journal-title":"Nature"},{"key":"1409_CR11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/annonc\/mdh150","volume":"15","author":"T S\u00fcdhoff","year":"2004","unstructured":"S\u00fcdhoff T, Enderle M-D, Pahlke M, Petz C, Teschendorf C, Graeven U, et al. 5-fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15:661\u20134.","journal-title":"Ann Oncol"},{"key":"1409_CR12","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/oxfordjournals.eurheartj.a059919","volume":"12","author":"RJ Luwaert","year":"1991","unstructured":"Luwaert RJ, Descamps O, Majois F, Chaudron JM, Beauduin M. Coronary artery spasm induced by 5-fluorouracil. Eur Heart J. 1991;12:468\u201370.","journal-title":"Eur Heart J"},{"key":"1409_CR13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.15420\/icr.2019.12","volume":"14","author":"JH Chong","year":"2019","unstructured":"Chong JH, Ghosh AK. Coronary artery vasospasm induced by 5-fluorouracil: proposed mechanisms, existing management options and future directions. Interv Cardiol. 2019;14:89\u201394.","journal-title":"Interv Cardiol"},{"key":"1409_CR14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2050-6511-15-47","volume":"15","author":"A Polk","year":"2014","unstructured":"Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15:47.","journal-title":"BMC Pharmacol Toxicol"},{"key":"1409_CR15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4103\/0973-1482.103530","volume":"8","author":"K Shah","year":"2012","unstructured":"Shah K, Gupta S, Ghosh J, Bajpai J, Maheshwai A. Acute non-ST elevation myocardial infarction following paclitaxel administration for ovarian carcinoma: a case report and review of literature. J Cancer Res Ther. 2012;8:442\u20134.","journal-title":"J Cancer Res Ther"},{"key":"1409_CR16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0049-3848(00)00294-2","volume":"99","author":"GI Togna","year":"2000","unstructured":"Togna GI, Togna AR, Franconi M, Caprino L. Cisplatin triggers platelet activation. Thromb Res. 2000;99:503\u20139.","journal-title":"Thromb Res"},{"key":"1409_CR17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/10623320802092161","volume":"15","author":"H Gallagher","year":"2008","unstructured":"Gallagher H, Carroll WM, Dowd M, Rochev Y. The effects of vinblastine on endothelial cells. Endothelium. 2008;15:9\u201315.","journal-title":"Endothelium"},{"key":"1409_CR18","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","volume":"28","author":"HS Haugnes","year":"2010","unstructured":"Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular Cancer: a 20-year follow-up study. JCO. 2010;28:4649\u201357.","journal-title":"JCO"},{"key":"1409_CR19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","volume":"12","author":"RM Touyz","year":"2018","unstructured":"Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies\u2013focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12:409\u201325.","journal-title":"J Am Soc Hypertens"},{"key":"1409_CR20","first-page":"775","volume":"18","author":"F Sen","year":"2013","unstructured":"Sen F, Yildiz I, Basaran M, Ekenel M, Oz F, Kilic L, et al. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib. J BUON. 2013;18:775\u201381.","journal-title":"J BUON"},{"key":"1409_CR21","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ijcard.2013.03.010","volume":"168","author":"S Winnik","year":"2013","unstructured":"Winnik S, Lohmann C, Siciliani G, von Lukowicz T, Kuschnerus K, Kraenkel N, et al. Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis \u2013 implications for cardiovascular safety. Int J Cardiol. 2013;168:2453\u201361.","journal-title":"Int J Cardiol"},{"key":"1409_CR22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/1471-2407-12-231","volume":"12","author":"MA Pantaleo","year":"2012","unstructured":"Pantaleo MA, Mandrioli A, Saponara M, Nannini M, Erente G, Lolli C, et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012;12:231.","journal-title":"BMC Cancer"},{"key":"1409_CR23","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1161\/CIRCRESAHA.114.303200","volume":"114","author":"JM Duran","year":"2014","unstructured":"Duran JM, Makarewich CA, Trappanese D, Gross P, Husain S, Dunn J, et al. Sorafenib cardiotoxicity increases mortality after myocardial infarction. Circ Res. 2014;114:1700\u201312.","journal-title":"Circ Res"},{"key":"1409_CR24","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","volume":"103","author":"E Amir","year":"2011","unstructured":"Amir E, Seruga B, Niraula S, Carlsson L, Oca\u00f1a A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. JNCI: J Nat Cancer Inst. 2011;103:1299\u2013309.","journal-title":"JNCI: J Nat Cancer Inst"},{"key":"1409_CR25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/07357907.2014.880452","volume":"32","author":"B Seruga","year":"2014","unstructured":"Seruga B, Zadnik V, Kuhar CG, Marinko T, Cufer T, Zakotnik B, et al. Association of aromatase inhibitors with coronary heart disease in women with early breast cancer. Cancer Investig. 2014;32:99\u2013104.","journal-title":"Cancer Investig"},{"key":"1409_CR26","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","volume":"302","author":"A Nanda","year":"2009","unstructured":"Nanda A, Chen M-H, Braccioforte MH, Moran BJ, D\u2019Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease\u2013induced congestive heart failure or myocardial infarction. JAMA. 2009;302:866\u201373.","journal-title":"JAMA"},{"key":"1409_CR27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","volume":"116","author":"DR Ziehr","year":"2015","unstructured":"Ziehr DR, Chen M-H, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, et al. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer: ADT and cardiac-specific mortality in men with prostate cancer. BJU Int. 2015;116:358\u201365.","journal-title":"BJU Int"},{"key":"1409_CR28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eururo.2019.07.031","volume":"77","author":"G Lu-Yao","year":"2020","unstructured":"Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol. 2020;77:158\u201366.","journal-title":"Eur Urol"},{"key":"1409_CR29","first-page":"306","volume-title":"5 flourouracil-induced apical ballooning syndrome: a case report: blood coagulation & fibrinolysis","author":"M Gianni","year":"2009","unstructured":"Gianni M, Dentali F, Lonn E. 5 flourouracil-induced apical ballooning syndrome: a case report: blood coagulation & fibrinolysis, vol. 20; 2009. p. 306\u20138."},{"key":"1409_CR30","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","volume":"39","author":"A Polk","year":"2013","unstructured":"Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974\u201384.","journal-title":"Cancer Treat Rev"},{"key":"1409_CR31","first-page":"215","volume":"10","author":"A Shahrokni","year":"2009","unstructured":"Shahrokni A, Rajebi MR, Harold L, Saif MW. Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene. JOP. 2009;10:215\u201320.","journal-title":"JOP"},{"key":"1409_CR32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1445-5994.2009.02144.x","volume":"40","author":"T Stewart","year":"2010","unstructured":"Stewart T, Pavlakis N, Ward M. Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Intern Med J. 2010;40:303\u20137.","journal-title":"Intern Med J"},{"key":"1409_CR33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1524-4741.2011.01120.x","volume":"17","author":"C Lestuzzi","year":"2011","unstructured":"Lestuzzi C, Tartuferi L, Corona G. Capecitabine (and 5 fluorouracil) cardiotoxicity. Metabolic considerations. Breast J. 2011;17:564\u20135 author reply 566-567.","journal-title":"Breast J"},{"key":"1409_CR34","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.amjcard.2012.07.026","volume":"110","author":"AP Ambrosy","year":"2012","unstructured":"Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol. 2012;110:1623\u20136.","journal-title":"Am J Cardiol"},{"key":"1409_CR35","first-page":"498","volume":"10","author":"C Schrader","year":"2005","unstructured":"Schrader C, Keussen C, Bewig B, von Freier A, Lins M. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res. 2005;10:498\u2013501.","journal-title":"Eur J Med Res"},{"key":"1409_CR36","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1200\/JCO.1991.9.9.1704","volume":"9","author":"EK Rowinsky","year":"1991","unstructured":"Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9:1704\u201312.","journal-title":"J Clin Oncol"},{"key":"1409_CR37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2605.1987.tb00204.x","volume":"10","author":"BL Samuels","year":"1987","unstructured":"Samuels BL, Vogelzang NJ, Kennedy BJ. Vascular toxicity following vinblastine, bleomycin, and cisplatin therapy for germ cell tumours. Int J Androl. 1987;10:363\u20139.","journal-title":"Int J Androl"},{"key":"1409_CR38","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/oxfordjournals.eurheartj.a062542","volume":"9","author":"T Stefenelli","year":"1988","unstructured":"Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988;9:552\u20136.","journal-title":"Eur Heart J"},{"key":"1409_CR39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/07357909009018924","volume":"8","author":"S Berliner","year":"1990","unstructured":"Berliner S, Rahima M, Sidi Y, Teplitsky Y, Zohar Y, Nussbaum B, et al. Acute coronary events following Cisplatin-based chemotherapy. Cancer Investig. 1990;8:583\u20136.","journal-title":"Cancer Investig"},{"key":"1409_CR40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7326\/0003-4819-105-1-48","volume":"105","author":"DC Doll","year":"1986","unstructured":"Doll DC. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105:48.","journal-title":"Ann Intern Med"},{"key":"1409_CR41","first-page":"927","volume":"19","author":"M Jafri","year":"2008","unstructured":"Jafri M. Protheroe a. Cisplatin-associated thrombosis: anti-cancer drugs. 2008;19:927\u20139.","journal-title":"Cisplatin-associated thrombosis: anti-cancer drugs"},{"key":"1409_CR42","first-page":"E18","volume":"26","author":"KO Karabay","year":"2014","unstructured":"Karabay KO, Yildiz O, Aytekin V. Multiple coronary thrombi with cisplatin. J Invasive Cardiol. 2014;26:E18\u201320.","journal-title":"J Invasive Cardiol"},{"key":"1409_CR43","first-page":"748","volume":"12","author":"S Schwarzer","year":"1991","unstructured":"Schwarzer S, Eber B, Greinix H, Lind P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J. 1991;12:748\u201350.","journal-title":"Eur Heart J"},{"key":"1409_CR44","doi-asserted-by":"crossref","first-page":"e66721","DOI":"10.1371\/journal.pone.0066721","volume":"8","author":"X-L Chen","year":"2013","unstructured":"Chen X-L, Lei Y-H, Liu C-F, Yang Q-F, Zuo P-Y, Liu C-Y, et al. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One. 2013;8:e66721.","journal-title":"PLoS One"},{"key":"1409_CR45","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","volume":"99","author":"FA Scappaticci","year":"2007","unstructured":"Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. JNCI J\\ Nat Cancer Ins. 2007;99:1232\u20139.","journal-title":"JNCI J\\ Nat Cancer Ins"},{"key":"1409_CR46","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","volume":"22","author":"FAB Schutz","year":"2011","unstructured":"Schutz FAB, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol. 2011;22:1404\u201312.","journal-title":"Ann Oncol"},{"key":"1409_CR47","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","volume":"49","author":"V Ranpura","year":"2010","unstructured":"Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49:287\u201397.","journal-title":"Acta Oncol"},{"key":"1409_CR48","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","volume":"20","author":"G Di Lorenzo","year":"2009","unstructured":"Di Lorenzo G, Autorino R, Bruni G, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol. 2009;20:1535\u201342.","journal-title":"Ann Oncol"},{"key":"1409_CR49","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","volume":"56","author":"MHW Kappers","year":"2010","unstructured":"Kappers MHW, van Esch JHM, Sluiter W, Sleijfer S, Danser AHJ, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor Sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56:675\u201381.","journal-title":"Hypertension"},{"key":"1409_CR50","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","volume":"28","author":"TK Choueiri","year":"2010","unstructured":"Choueiri TK, Schutz FAB, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. JCO. 2010;28:2280\u20135.","journal-title":"JCO"},{"key":"1409_CR51","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1200\/JCO.2012.42.4911","volume":"30","author":"G Numico","year":"2012","unstructured":"Numico G, Sicuro M, Silvestris N, Mozzicafreddo A, Trogu A, Malossi A, et al. Takotsubo syndrome in a patient treated with sunitinib for renal cancer. JCO. 2012;30:e218\u201320.","journal-title":"JCO"},{"key":"1409_CR52","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s10637-010-9500-9","volume":"29","author":"S Ropert","year":"2011","unstructured":"Ropert S, Vignaux O, Mir O, Goldwasser F. VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption. Investig New Drugs. 2011;29:1497\u20139.","journal-title":"Investig New Drugs"},{"key":"1409_CR53","doi-asserted-by":"crossref","unstructured":"Goss PE, Piccart MJ, Pritchard KI, Perez EA. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. N Engl J Med. 2003:10.","DOI":"10.1056\/NEJMoa032312"},{"key":"1409_CR54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF02710012","volume":"7","author":"JC Galcer\u00e1n","year":"2005","unstructured":"Galcer\u00e1n JC, Piulats RB, Mart\u00edn-Broto J, Rey PM, Aligu\u00e9 MN, Santasusana MD, et al. A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer. Clin Transl Oncol. 2005;7:66\u201373.","journal-title":"Clin Transl Oncol"},{"key":"1409_CR55","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1442-2042.2010.02544.x","volume":"17","author":"Y Nakagami","year":"2010","unstructured":"Nakagami Y, Ohori M, Sakamoto N, Koga S, Hamada R, Hatano T, et al. Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients. Int J Urol. 2010;17:629\u201334.","journal-title":"Int J Urol"},{"key":"1409_CR56","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/cncr.20673","volume":"101","author":"GM Lubiniecki","year":"2004","unstructured":"Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma. Cancer. 2004;101:2755\u20139.","journal-title":"Cancer"},{"key":"1409_CR57","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Br\u00f8nnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987\u201398.","journal-title":"N Engl J Med"},{"key":"1409_CR58","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ccd.26379","volume":"87","author":"CA Iliescu","year":"2016","unstructured":"Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, et al. SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory. Cathet Cardiovasc Intervent. 2016;87:202\u201323.","journal-title":"Cathet Cardiovasc Intervent"},{"key":"1409_CR59","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2015.65","volume":"12","author":"MS Ewer","year":"2015","unstructured":"Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12:547\u201358.","journal-title":"Nat Rev Cardiol"},{"key":"1409_CR60","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","volume":"70","author":"H-M Chang","year":"2017","unstructured":"Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of Cancer therapy: best practices in diagnosis, prevention, and management\u2014part 1. J Am Coll Cardiol. 2017;70:2536\u201351.","journal-title":"J Am Coll Cardiol"},{"key":"1409_CR61","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2019.11.059","volume":"75","author":"JM Bonsu","year":"2020","unstructured":"Bonsu JM, Guha A, Charles L, Yildiz VO, Wei L, Baker B, et al. Reporting of cardiovascular events in clinical trials supporting FDA approval of contemporary cancer therapies. J Am Coll Cardiol. 2020;75:620\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1409_CR62","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u201355.","journal-title":"N Engl J Med"},{"key":"1409_CR63","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"1409_CR64","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0368-1319(64)80043-0","volume":"4","author":"GDGH Amromin","year":"1964","unstructured":"Amromin GDGH. The synergism of x-irradiation and cholesterol-fat feeding on the development of coronary artery lesions. J Atheroscler Res. 1964;4:325\u201334.","journal-title":"J Atheroscler Res"},{"key":"1409_CR65","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2307\/3576813","volume":"107","author":"ML Evans","year":"1986","unstructured":"Evans ML, Graham MM, Mahler PA, Rasey JS. Changes in vascular permeability following thorax irradiation in the rat. Radiat Res. 1986;107:262\u201371.","journal-title":"Radiat Res"},{"key":"1409_CR66","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2353\/ajpath.2006.050409","volume":"168","author":"FA Stewart","year":"2006","unstructured":"Stewart FA, Heeneman S, te Poele J, Kruse J, Russell NS, Gijbels M, et al. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE\u2212\/\u2212 mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am J Pathol. 2006;168:649\u201358.","journal-title":"Am J Pathol"},{"key":"1409_CR67","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0735-1097(00)01190-6","volume":"37","author":"JA Beckman","year":"2001","unstructured":"Beckman JA, Thakore A, Kalinowski BH, Harris JR, Creager MA. Radiation therapy impairs endothelium-dependent vasodilation in humans. J Am Coll Cardiol. 2001;37:761\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"1409_CR68","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","volume":"290","author":"MC Hull","year":"2003","unstructured":"Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831\u20137.","journal-title":"JAMA"},{"key":"1409_CR69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2006.07.0805","volume":"25","author":"PA Heidenreich","year":"2007","unstructured":"Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin\u2019s disease. J Clin Oncol. 2007;25:43\u20139.","journal-title":"J Clin Oncol"},{"key":"1409_CR70","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0002-9343(81)90574-X","volume":"70","author":"FC Brosius","year":"1981","unstructured":"Brosius FC, Waller BF, Roberts WC. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med. 1981;70:519\u201330.","journal-title":"Am J Med"},{"key":"1409_CR71","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ccd.21109","volume":"70","author":"K Sch\u00f6mig","year":"2007","unstructured":"Sch\u00f6mig K, Ndrepepa G, Mehilli J, Pache J, Kastrati A, Sch\u00f6mig A. Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. Catheter Cardiovasc Interv. 2007;70:359\u201365.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1409_CR72","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/CIRCULATIONAHA.118.034392","volume":"138","author":"P Libby","year":"2018","unstructured":"Libby P, Ebert BL. CHIP (clonal hematopoiesis of indeterminate potential): potent and newly recognized contributor to cardiovascular risk. Circulation. 2018;138:666\u20138.","journal-title":"Circulation"},{"key":"1409_CR73","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"\u2022 Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398 Important translational study evaluating specific mutations in CHIP patients and risk for CAD and MI.","journal-title":"N Engl J Med"},{"key":"1409_CR74","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111\u201321.","journal-title":"N Engl J Med"},{"key":"1409_CR75","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1161\/CIRCULATIONAHA.113.003199","volume":"128","author":"W Van Tassell Benjamin","year":"2013","unstructured":"Van Tassell Benjamin W, Stefano T, Eleonora M, Antonio A. Targeting Interleukin-1 in heart disease. Circulation. 2013;128:1910\u201323.","journal-title":"Circulation"},{"key":"1409_CR76","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1001\/jama.286.17.2107","volume":"286","author":"E Lindmark","year":"2001","unstructured":"Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001;286:2107\u201313.","journal-title":"JAMA"},{"key":"1409_CR77","doi-asserted-by":"crossref","unstructured":"Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018:10.","DOI":"10.1126\/scitranslmed.aan8292"},{"key":"1409_CR78","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/cncr.22434","volume":"109","author":"MG Sarkiss","year":"2007","unstructured":"Sarkiss MG, Yusuf SW, Warneke CL, Botz G, Lakkis N, Hirch-Ginsburg C, et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer. 2007;109:621\u20137.","journal-title":"Cancer"},{"key":"1409_CR79","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","volume":"53","author":"JW van Werkum","year":"2009","unstructured":"van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, et al. Predictors of coronary stent thrombosis. J Am Coll Cardiol. 2009;53:1399\u2013409.","journal-title":"J Am Coll Cardiol"},{"key":"1409_CR80","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","volume":"355","author":"KC Oeffinger","year":"2006","unstructured":"Oeffinger KC, Kawashima T, Friedman DL, Kadan-Lottick NS, Robison LL. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572\u201382.","journal-title":"N Engl J Med"},{"key":"1409_CR81","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2017.11.29","volume":"5","author":"NV Pothineni","year":"2017","unstructured":"Pothineni NV, Shah NN, Rochlani Y, Saad M, Kovelamudi S, Marmagkiolis K, et al. Temporal trends and outcomes of acute myocardial infarction in patients with cancer. Ann Transl Med. 2017;5:482\u20135.","journal-title":"Ann Transl Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-020-01409-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-020-01409-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-020-01409-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T21:48:13Z","timestamp":1669153693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-020-01409-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1409"],"URL":"https:\/\/doi.org\/10.1007\/s11886-020-01409-8","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"type":"print","value":"1523-3782"},{"type":"electronic","value":"1534-3170"}],"subject":[],"published":{"date-parts":[[2020,10,10]]},"assertion":[{"value":"2 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Tyler B. Moran and Juan Carlos Plana declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"159"}}